P-211 Phase II study of docetaxel in combination with capecitabine in patients with previously treated non-small cell lung cancer (NSCLC)

MLA

Gerard J. Nuovo, et al. “P-211 Phase II Study of Docetaxel in Combination with Capecitabine in Patients with Previously Treated Non-Small Cell Lung Cancer (NSCLC).” Lung Cancer, vol. 41, Aug. 2003, pp. S144–45. EBSCOhost, https://doi.org/10.1016/s0169-5002(03)92180-5.

APA

Gerard J. Nuovo, Anterpreeet Neki, Miguel Villalona Calero, Richie Soong, Robert B. Diasio, Tamila Kindwall-Keller, Gregory A. Otterson, Chris Rhoades, & Tamara Criswell. (2003). P-211 Phase II study of docetaxel in combination with capecitabine in patients with previously treated non-small cell lung cancer (NSCLC). Lung Cancer, 41, S144–S145. https://doi.org/10.1016/s0169-5002(03)92180-5

Chicago

Gerard J. Nuovo, Anterpreeet Neki, Miguel Villalona Calero, Richie Soong, Robert B. Diasio, Tamila Kindwall-Keller, Gregory A. Otterson, Chris Rhoades, and Tamara Criswell. 2003. “P-211 Phase II Study of Docetaxel in Combination with Capecitabine in Patients with Previously Treated Non-Small Cell Lung Cancer (NSCLC).” Lung Cancer 41 (August): S144–45. doi:10.1016/s0169-5002(03)92180-5.